Thanks Numbers, I made some (quick) DD on those names.
Here are my findings:
- Only public company is Acura
- couldn't find anything on Elysium O2P
- ALTAIR and ACURA are in the pre-clinical/clinical phase
- LIMITX status of development not disclosed
ALITAIR – PRIVATE COMPANY
Alitair Overdose Reduction
ODR™ is a drug delivery technology that functions passively as part of a drug’s dosage form, limiting the amount of drug released in the digestive system based on the total amount of drug ingested. With ODR™, safety is built in to the dosage form using approved excipients and well-established manufacturing technology.
Abuse Deterrence Properties Inherent to ODR™
ODR™ has the potential to protect patients from prescription drug overdose, and ODR™ also includes abuse deterrence properties. Our ODR™ technology cannot be circumvented by means commonly employed today, such as crushing the capsules or tablets and smoking or snorting the actives.
Initial tests indicate that ODR™ will work across a broad range of prescription drugs including opioids, anti-depressants and tranquilizers. Clinical testing in humans is the next step for ODR™.
Significant Market Opportunity for ODR™
Initial tests indicate that ODR™ will work across a broad range of prescription drugs including opioids, anti-depressants and tranquilizers. Clinical testing in humans is the next step for ODR™. We estimate the market at 200 million prescriptions. At a price of approximately $100 per prescription for products utilizing ODR™, ODR™ represents a $20 billion market opportunity.
ACURA – acur us
LIMITX™ Technology
intended to address an oral Excessive Tablet Abuse (ETA) or accidental consumption of multiple tablets and provide a margin of safety during accidental over-ingestion of tablets. LIMITX™ is also expected to exhibit barriers to abuse by snorting and injection.
LTX-04 is currently being reformulated to provide faster release of active ingredient when 1 and 2 tablets are ingested. The initial formulation of LTX-04 was supported by a grant from the National Institute On Drug Abuse of the National Institutes of Health under Award Number R44DA037921.
Kashiv Pharma iADOPT
Abuse Deterrent Overdose Protection Technology
Kashiv’s next generation of advanced Abuse Deterrent Formulation (ADF) drug delivery systems are based on a combination of physical/chemical barriers to prevent or reduce:
• mechanical manipulation of dosage form to crush, cut, grate, or grind
• drug extraction using a variety of aqueous and alcohol based solvents
• drug exposure from intentional and accidental overdose.
These technologies are designed to make dosage forms difficult to manipulate or abuse. The resulting product would offer reduced euphoria compared to competitive ADF-based formulations and become the preferred choice of prescribing physicians
